Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP -2.35%60 EV-to-EBITDA is 6.32 as of Aug. 03, 2026, which is 33% above its 10-year median of 4.74. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 746 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 79.62% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Elite Pharmaceuticals's enterprise value is $374.5 Mil.
Elite Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $59.2 Mil. Therefore, Elite Pharmaceuticals's EV-to-EBITDA for today is 6.32.
The historical rank and industry rank for Elite Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ELTP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -640.02 Med: 4.74 Max: 568.87
Current: 6.32
During the past 13 years, the highest EV-to-EBITDA of Elite Pharmaceuticals was 568.87. The lowest was -640.02. And the median was 4.74.
ELTP's EV-to-EBITDA is ranked better than 79.62% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.015
vs ELTP: 6.32
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Elite Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Elite Pharmaceuticals's share price for today is $0.37.
Elite Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Elite Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's EV-to-EBITDA falls into.
Elite Pharmaceuticals's current Enterprise Value is $374.5 Mil.
Elite Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $59.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals (ELTP) has a EV-to-EBITDA of 6.32 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elite Pharmaceuticals. This is 33% above median its historical median of 4.74. According to the industry distribution chart, Elite Pharmaceuticals ranks #152 out of 746 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Elite Pharmaceuticals' EV-to-EBITDA too high?
Elite Pharmaceuticals' current EV-to-EBITDA of 6.32 is 33% above median its 10-year median of 4.74. The Drug Manufacturers industry median EV-to-EBITDA is 13.02. Elite Pharmaceuticals' value of 6.32 is 51.4% below this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #152 out of 746 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' EV-to-EBITDA compare to EOLS and EBS?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #152 out of 746 companies for EV-to-EBITDA. This places Elite Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.02. Elite Pharmaceuticals' value of 6.32 is 51.4% below this benchmark. While the company's 10-year median is 4.74 vs. the industry median of 13.02, Elite Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current EV-to-EBITDA of 6.32 is 51.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elite Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current EV-to-EBITDA is 6.32, which is 33% above median its own 10-year median of 4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.37 — trading 35.1% below its estimated fair value. The current EV-to-EBITDA is 6.32, which is 33% above median its 10-year median of 4.74 and 51.4% below the Drug Manufacturers industry median of 13.02. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current EV-to-EBITDA is 6.32 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.37 is trading 35.1% below its estimated GF Value™ of $0.57.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
EV-to-EBITDA: 6.32 (33% above median its 10-year median of 4.74)
GF Value™: $0.57 vs. price of $0.37 (35.1% below fair value)
Industry Position: 51.4% below the Drug Manufacturers median (#152 of 746)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
